TAVR Guidelines for High-Risk Patients with Severe Aortic Stenosis

Primary Recommendation

The American College of Cardiology recommends TAVR for patients with severe symptomatic aortic stenosis who are at high surgical risk, provided they have suitable aortic and vascular anatomy, predicted survival >12 months, and an estimated ≥50% risk of mortality or irreversible morbidity at 30 days from surgical aortic valve replacement 1

A patient is considered high-risk for surgical aortic valve replacement if they have an STS score ≥8%, which makes TAVR a reasonable alternative 1
Comorbidities such as diabetes, hypertension, and impaired renal function contribute to surgical risk, according to the American College of Cardiology 1
Additional high-risk features to assess include frailty status, prior radiation therapy, porcelain aorta, severe hepatic or pulmonary disease, as recommended by the American College of Cardiology 1
The American College of Cardiology requires a multidisciplinary Heart Valve Team assessment for all TAVR decisions, including interventional cardiologists, cardiac surgeons, cardiac imaging specialists, anesthesiologists, and heart failure specialists 2, 3

The American College of Cardiology recommends CT angiography of chest, abdomen, and pelvis with ECG-gated thoracic acquisition for pre-procedure anatomic evaluation 3
Key anatomic assessments include iliofemoral vessel diameter with minimal calcification for transfemoral access, aortic annulus sizing, coronary ostia height, and aortic root calcification distribution, as specified by the American College of Cardiology 3
The American College of Cardiology requires transthoracic echocardiography to confirm maximum aortic velocity, mean aortic valve gradient, aortic valve area, left ventricular ejection fraction, pulmonary artery pressure estimate, and mitral valve assessment 3, 4, 5

The American College of Cardiology recommends specific modifications for patients with impaired renal function, including minimizing contrast exposure during CT angiography and considering alternative imaging with cardiac MRI if contrast is contraindicated 3
The American College of Cardiology assesses the risk of acute kidney injury post-procedure, which is particularly relevant for patients with existing renal impairment 1, 3

The American College of Cardiology reports TAVR-related complications, including mortality (3-5% at 30 days), stroke (6-7%), vascular access complications (17%), permanent pacemaker requirement (2-43% depending on valve type), and paravalvular aortic regurgitation 1, 4, 6
The American College of Cardiology compares TAVR risks to surgical AVR risks, including mortality (3%), stroke (2%), and prolonged ventilation (11%) 1, 4

The American College of Cardiology recommends against TAVR if expected benefit is less than expected risk, with futility indicators including multiple organ system failure, severe frailty, advanced cognitive impairment, life expectancy <12 months from non-cardiac causes, and patient goals incompatible with realistic procedural outcomes 1, 3, 4

The American College of Cardiology requires transthoracic echocardiography to assess maximum aortic velocity, mean gradient, aortic valve area, paravalvular and valvular regurgitation severity, left ventricular function, and pulmonary pressure immediately post-TAVR 3, 4, 6
The American College of Cardiology recommends serial echocardiography at specified intervals for long-term surveillance to monitor valve function, paravalvular regurgitation progression, and ventricular remodeling 3

The 2012 European Society of Cardiology (ESC) guideline lists LVEF < 20 % as a relative contraindication for TAVI, but not an absolute one, indicating that patients with very low systolic function may still be considered after careful evaluation. 7
According to the same ESC guideline, LVEF between 20 % and 35 % is not mentioned as a contraindication, so patients in this range are acceptable candidates for TAVI. 7

The ESC 2012 guideline designates severe pulmonary hypertension as a relative contraindication only for the trans‑apical TAVI approach, while transfemoral access remains permissible. 7
The 2008 ESC/EACTS position statement similarly states that severe respiratory insufficiency (including severe PH) contraindicates the trans‑apical route but does not limit transfemoral TAVI. [8][9]10

Data from the Journal of the American College of Cardiology (JACC) 2012 study show that pre‑existing PH predicts both 30‑day and 1‑year mortality after TAVI, with a risk magnitude comparable to major vascular complications and renal insufficiency. 11
The same JACC analysis reports that patients with PH have a higher susceptibility to intra‑procedural hemodynamic and electrical instability, necessitating vigilant monitoring. 11
Right‑heart failure and severe tricuspid regurgitation frequently complicate the management of PH patients undergoing TAVI, contributing to adverse outcomes. 11
Despite these heightened risks, PH is not an absolute contraindication for TAVI when appropriate patient selection and procedural planning are performed. 11

The JACC 2012 recommendation advises that right‑heart catheterization should be considered in TAVI candidates with PH to accurately characterize the severity and underlying mechanism (post‑capillary vs. pre‑capillary) before proceeding. 11